Search results for " lymphoma"

showing 10 items of 448 documents

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

2009

Abstract Background/Aim Data on management and long-term follow-up of Helicobacter pylori -associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. Methods This study enrolled patients with stages I–II 1 MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. Results Sixty patients (stage I/II 1 : 50/10) were followed up for a median t…

AdultMaleVincristinemedicine.medical_specialtyCyclophosphamideSettore MED/12 - GASTROENTEROLOGIAGastric maltomamanagementKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalHelicobacter InfectionsYoung AdultStomach Neoplasmsimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultCyclophosphamideAgedRetrospective StudiesAged 80 and overHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyProton Pump InhibitorsMALT lymphomaRetrospective cohort studyLymphoma B-Cell Marginal ZoneMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsLymphomaSurgeryItalyDoxorubicinVincristinePrednisoneFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

Trends in excess mortality in follicular lymphoma at a population level

2015

Background Since the 1990s and since the development of humanised monoclonal antibodies in 1998, the treatment of non-Hodgkin lymphoma has undergone profound changes. Follicular lymphoma (FL) was the first to benefit from this treatment, and several clinical trials have shown a significant improvement in overall survival, but little information is available at a population level. Objective Our objective was to estimate changes in FL-specific mortality at a population level, with an appropriate methodology. Methods Two French retrospective population-based studies on FL were conducted, one from 1995 to 2004, in 1477 patients, and one from 1995 to 2010, in 451 patients. Trends in excess morta…

AdultMalemedicine.medical_specialtyAdolescentPopulation level[SDV]Life Sciences [q-bio]PopulationFollicular lymphomaHistory 21st CenturyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineIn patientRegistriesAge of OnsetStage (cooking)educationLymphoma FollicularAgedNeoplasm StagingRetrospective StudiesAged 80 and overExcess mortalityeducation.field_of_studybusiness.industryHematologyGeneral MedicineHistory 20th CenturyMiddle Agedmedicine.disease3. Good healthLymphomaClinical trialPopulation Surveillance030220 oncology & carcinogenesisImmunologyFemaleFrancebusiness030215 immunology
researchProduct

Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome

2003

Background: High serum levels of soluble intercellular adhesion molecule-1(s-ICAM-1/s-CD54) have been associated with adverse clinical features and poor outcome in chronic lymphocytic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, but their value in the different subtypes of non-Hodgkin’s lymphoma has not been well addressed. Patients and methods: Our aim was to study the serum levels of s-ICAM-1 in diffuse large B-cell lymphoma (DLBCL) and to correlate them with clinical characteristics and outcome. We analyzed the serum levels of s-ICAM-1 in a series of 55 patients with DLBCL diagnosed in a single institution. s-ICAM-1 levels were quantified by an immunoenzymatic assay. Median ag…

AdultMalemedicine.medical_specialtyPathologyLymphoma B-CellChronic lymphocytic leukemiaGastroenterologyImmunoenzyme TechniquesInternational Prognostic IndexRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansSurvival analysisAgedAged 80 and overL-Lactate DehydrogenaseBeta-2 microglobulinbusiness.industryLymphoma Non-HodgkinLarge-cell lymphomaHematologyMiddle AgedIntercellular Adhesion Molecule-1Prognosismedicine.diseaseSurvival AnalysisLymphomaTreatment OutcomeOncologyB symptomsCase-Control StudiesLymphatic MetastasisDisease ProgressionFemaleLymphoma Large B-Cell Diffusemedicine.symptombusinessDiffuse large B-cell lymphomaAnnals of Oncology
researchProduct

Risk of Non-Hodgkin Lymphoma in Celiac Disease

2002

CONTEXT: Celiac disease is one of the most common lifelong disorders. Non-Hodgkin lymphoma is a possible complication of celiac disease and may lead to a large portion of lymphoma cases. OBJECTIVE: To quantify the risk for developing non-Hodgkin lymphoma of any primary site associated with celiac disease. DESIGN AND SETTING: Multicenter, case-control study conducted between January 1996 and December 1999 throughout Italy. PATIENTS: Cases were older than 20 years (median, 57; range, 20-92 years) with non-Hodgkin lymphoma of any primary site and histological type and were recruited at the time of the diagnosis. Controls were healthy adults (2739 men and 2981 women) from the general population…

AdultMalemedicine.medical_specialtyPathologyLymphoma B-CellSettore MED/09 - Medicina InternaPopulationLymphoma T-CellNon-Hodgkin lymphoma; celiac diseaseGastroenterologyCoeliac diseaseRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineImmunopathologymedicineHumansT-cell lymphomaNon-hodgkin diseaseeducationMass screeningAgedNon-Hodgkin lymphomaAged 80 and overeducation.field_of_studybusiness.industryLymphoma Non-HodgkinCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaCase-Control StudiesFemalebusinessceliac diseaseJAMA
researchProduct

Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century.

2013

Summary Treatment for Hodgkin lymphoma (HL) is more aggressive in Germany than in the United States (US) and differences in treatment may lead to differences in population level survival. Patients diagnosed with HL in 11 German states in 1997–2006 were included in the analyses and were compared to similar analyses from patients in the Surveillance, Epidemiology, and End Results database in the US. Period analysis was used to calculate 5-year relative survival for the time period of 2002–2006 overall and by gender, age and histology. Overall 5-year relative survival for patients with HL in Germany was 84·3%, compared to 80·6% for the US. Survival was highest in patients aged 15–29 years at 9…

AdultMalemedicine.medical_specialtyPediatricsPopulation levelPopulationLate toxicityOlder patientsGermanyEpidemiologyMedicineHumanseducationeducation.field_of_studyRelative survivalbusiness.industryAge FactorsHematologyMiddle AgedHodgkin DiseaseSurvival AnalysisSurvival RateHodgkin lymphomaPeriod AnalysisFemalebusinessBritish journal of haematology
researchProduct

Photochemotherapy Alone or Combined with Interferon Alpha-2a in the Treatment of Cutaneous T-Cell Lymphoma

1990

Eighty-two patients with either mycosis fungoides (MF) or parapsoriasis en plaques were treated with psoralens ultraviolet A light (PUVA). Clinical and histologic parameters were followed for a period from 6 months to 10 years. Complete clinical clearing of lesions was observed in 51 patients (62%) and most of them were in limited-plaque MF group or parapsoriasis en plaque. The mean total dose of PUVA for complete clearing was less for early MF. Thirty-one patients (38%) relapsed and responded to additional PUVA. Patients in early stages of the disease remained clear for up to 68 months after the first course of PUVA. Post-treatment skin biopsies with early MF showed histologic clearing. A …

AdultMalemedicine.medical_specialtySkin NeoplasmsCombination therapyConstitutional symptomsDermatologyInterferon alpha-2BiochemistryMycosis FungoidesInterferonmedicineHumansSezary SyndromePUVA TherapyMolecular BiologyDepression (differential diagnoses)AgedNeoplasm StagingMycosis fungoidesParapsoriasisbusiness.industryCutaneous T-cell lymphomaInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseCombined Modality TherapyDermatologyRecombinant ProteinsLymphoma T-Cell CutaneousDrug EvaluationFemalebusinessProgressive diseasemedicine.drugJournal of Investigative Dermatology
researchProduct

Subtype-specific incidence of testicular cancer in Germany: a pooled analysis of nine population-based cancer registries.

2009

Summary Comparisons of incidence estimates of testicular cancer subtypes beyond seminoma and non-seminoma are virtually missing in the epidemiologic literature. We analysed incidence data from population-based German cancer registries to provide subtype-specific incidences of testicular cancer. We pooled data from nine cancer registries from 1998 to 2003. We estimated incidence and mortality time trends of West and East Germany. Incidence and mortality were standardized by the European standard population. The annual percentage incidence change from 1961 through 1989 was 4.9% in East Germany and 3.0% from 1970 through 2004 in Saarland. Incidence increases were the most pronounced among adol…

AdultMalemedicine.medical_specialtyTime Factorsendocrine system diseasesAdolescentUrologyEndocrinology Diabetes and MetabolismPopulationPopulation basedEmbryonal carcinomaYoung AdultAge DistributionTesticular NeoplasmsCarcinoma EmbryonalGermanymedicineHumansChoriocarcinomaRegistrieseducationChildTesticular cancerAgedGynecologyAged 80 and overeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceInfant NewbornTeratomaCancerInfantSeminomaMiddle Agedmedicine.diseaseSeminomaReproductive MedicineTesticular LymphomaChild PreschoolPopulation SurveillancebusinessDemographyInternational journal of andrology
researchProduct

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term foll…

2010

Background Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. Design and Methods The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen w…

AdultMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentFollicular lymphomaHematopoietic stem cell transplantationGastroenterologyreduced intensity conditioningfollicular lymphomaallogeneic stem cell transplantationInternal medicinemedicinegraft-versus-host diseaseHumansTransplantation HomologousLymphoma FollicularSurvival ratebusiness.industryHistocompatibility TestingSiblingsHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseSurgeryFludarabineSurvival RateTransplantationTreatment OutcomeGraft-versus-host diseaseFemaleOriginal ArticleTransplantation ConditioningbusinessProgressive diseaseFollow-Up Studiesmedicine.drugHLA identical sibling donor
researchProduct

Burkitt lymphoma associated with human immunodeficiency virus infection and pulmonary tuberculosis: A case report.

2019

Abstract Introduction: The association of human immunodeficiency virus (HIV) infection with Burkitt lymphoma is related to the presence of Epstein Barr virus infection and the impact of the HIV antigen on the expansion of B-polyclonal cells. In Southeast Europe, the association is rare, and recognizing this is important in the therapeutic decision to increase patient survival rate. The association of HIV with Burkitt lymphoma and tuberculosis is even more rarely described in the literature. Patient concerns: We present the case of a 40-year-old patient who presented with a 3-week history of fever (max. 38.7 °C), painful axillary swelling on the right side, lumbar pain, gait disorders, heada…

AdultMalemedicine.medical_specialtyTuberculosisAntitubercular AgentsAntineoplastic AgentsHIV Infectionshuman immunodeficiency virus infectionNeurosurgical ProceduresMycobacterium tuberculosis03 medical and health sciences0302 clinical medicinePharmacotherapyFatal Outcomeimmune system diseasesInternal medicinehemic and lymphatic diseasesAntiretroviral Therapy Highly ActivemedicineHumans030212 general & internal medicineClinical Case ReportEpstein–Barr virus infectionTuberculosis PulmonaryImmunodeficiencydose-adjusted etoposide doxorubicin and cyclophosphamide with vincristine prednisone and rituximabbiologyClinical Deteriorationbusiness.industry4900BrainBurkitt lymphomaGeneral MedicineViral Loadhighly active antiretroviral therapymedicine.diseasebiology.organism_classificationDecompression SurgicalLymphomaCD4 Lymphocyte CountSpinal Cord030220 oncology & carcinogenesisSputummedicine.symptombusinessViral loadpulmonary tuberculosisResearch ArticleMedicine
researchProduct

MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

1990

Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group wi…

AdultMalemedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentLeucovorinSalvage therapyGastroenterologyBleomycinimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIntermediate GradeCyclophosphamideAgedChemotherapybusiness.industryLymphoma Non-HodgkinHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaSurgeryLymphomaMethotrexateDoxorubicinVincristinePrednisoneFemaleNeoplasm Recurrence LocalbusinessProgressive diseasemedicine.drugBlut
researchProduct